Key facts
- It has raised $66.5M across 2 recorded rounds; the latest was Early Stage VC ($23.3M) in Apr 2023.
- Notable investors include Labcorp Venture Fund, MSD Global Health Innovation Fund, Marshall Wace, Montage Capital, Maywic Select Investments — 16 tracked in total.
- Prognos Health has filed 3 Form Ds with the SEC since 2017, most recently May 2023 ($23.3M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Prognos Health
Funding rounds
2 roundsAbout Prognos Health
Developer of a healthcare analytics platform designed to utilize patient-level data to derive clinical insights. The company's platform leverages de-identified patients, multi-lab test data results, open and closed medical claims, as well as data to empower precise decision-making at all stages of the brand lifecycle and member enrollment, enabling medical companies to align brand strategy and risk assessment to clinical treatment decisions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2010
- Employees
- 61
- Website
- prognoshealth.com/
- Ownership
- Privately Held (backing)
Prognos Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prognos Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prognos Health in its N-PORT filings yet. We sweep new filings monthly.